Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

20150318 smb hve quirem medical jan sigger


Published on

  • Be the first to comment

  • Be the first to like this

20150318 smb hve quirem medical jan sigger

  1. 1. March 2015 QuiremSpheres® The Next Generation Microspheres for Radioembolisation “Treat what you see and see what you treat”
  2. 2. Agenda • Company Profile • Management Team • Cancer in the liver • The radioembolisation market • QuiremSpheres® • Company timeline • Main start-up challenges 2
  3. 3. • Spin-off in 2013 from the University Medical Center Utrecht • 20 years of development on Holmium microspheres • Superior proposition in fast growing radioembolisation market for liver malignancies • Higher dose rate ensures more effective tumor kill • Unique imaging capabilities enable personalized, real-time, image-guided treatment • Supported by state-of-the-art administration device and industry first SW treatment planning & evaluation solution • Preparing for product launch early 2015 • Strong IP position • Management team with proven track record Company Profile Superior proposition in fast growing market
  4. 4. Jan Sigger – Chief Executive Officer  Held senior management positions at Royal Dutch Shell and Akzo Nobel.  Joint Nucletron, the global market leader in brachytherapy, as CFO in 2008.  Transformed Nucletron into the fastest growing radiotherapy company and managed the sale from private equity ownership to Elekta AB in 2011. Jan Sigger Chief Executive Officer M: +31 6 20545977 Management Team Quirem Medical has a seasoned team with relevant experience Frank Nijsen – Chief Scientific Officer  Performed 20 years of research into Holmium microspheres.  Led the successful valorisation of the Holmium technology and was instrumental in the creation of the spin-off company Quirem Medical.  Holds as inventor many patents in the radioembolization field. Frank Nijsen Chief Scientific Officer M: +31 6 40675781
  5. 5. 5 * Globocan 2012 data High medical need Life expectancy is low for both primary and metastasized liver cancer
  6. 6. Liver: • 70% portal vein • 30% hepatic artery Tumor: • 99% hepatic artery Radioembolisation of the liver Maximising the dose to the tumor
  7. 7. MRI of distribution of paramagnetic QuiremSpheres - energy 1.84 MeV 166Ho - energy 81 keV 165Ho neutron QuiremSpheres® Neutron activation and characteristics
  8. 8. See what you treat and treat what you see Before treatment After treatment 19 Gy 135 Gy 35 Gy 19 Gy 135 Gy 35 Gy Anatomical MRI Nuclear imaging QuiremSpheres™ sensitive MRI Tumor 1 Tumor 2 • Personalized local treatment • Optimal radiation dose to the tumor • Minimal side effects • Treatment planning & evaluation (no more black box) • Follow-up treatment if needed Imaging capabilities QuiremSpheres® Enabling treatment planning & evaluation and real-time image guided treatment
  9. 9. 9 Clinical evidence is growing Successful phase 1 study, phase 2 study almost completed, 3rd and 4th study started, 5th study for intratumoral head & neck treatment recently approved Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose- escalation study Maarten Smits, Johannes Nijsen, Maurice van den Bosch, Marnix Lam, Maarten Vente, Willem Mali, Alfred van het Schip, Bernard Zonnenberg Lancet Oncology 2012 Oct;13(10):1025-34.
  10. 10. Main start-up challenges Make sure to timely address the key factors for success by creating: • The right team (priority 1,2 and 3) • The right information • Business plan • Financial plan • IP landscape • The right support • Legal • Financial • Regulatory • The right partners • Technical • Commercial • The right investors • Funding capabilities • Time horizon • Network 10
  11. 11. …a personalized way to fight liver cancer QuiremSpheres®